$ZOM
Zomedica Corp.

2020 Q4 Form 10-Q Financial Statement

#000117184320007889 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $3.171M $2.298M $1.394M
YoY Change 70.13% 36.47% 23.07%
% of Gross Profit
Research & Development $2.702M $3.908M
YoY Change 180.75% 268.17%
% of Gross Profit
Depreciation & Amortization $119.7K $78.20K $77.86K
YoY Change -41.25% 11.56% 12.96%
% of Gross Profit
Operating Expenses $4.128M $5.000M $5.303M
YoY Change 44.49% 419.55% 399.53%
Operating Profit -$5.000M -$5.303M
YoY Change 75.8% 121.77%
Interest Expense $5.350K $0.00 $0.00
YoY Change 2447.62% -100.0%
% of Operating Profit
Other Income/Expense, Net $1.140K $1.960K $0.00
YoY Change
Pretax Income -$4.173M -$4.980M -$5.308M
YoY Change 46.07% 75.0% 120.76%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.173M -$4.980M -$5.308M
YoY Change 46.07% 75.0% 120.76%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$7.148K -$9.046K -$24.71K
COMMON SHARES
Basic Shares Outstanding 564.1M 550.5M shares 214.8M
Diluted Shares Outstanding 550.5M shares 214.8M

Balance Sheet

Concept 2020 Q4 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.99M $52.03M $29.10M
YoY Change 12041.19% 1991.64% 399.87%
Cash & Equivalents $61.99M $52.03M $29.10M
Short-Term Investments
Other Short-Term Assets $727.8K $932.4K $782.7K
YoY Change -40.76% -37.73% -43.66%
Inventory $0.00
Prepaid Expenses $1.728M
Receivables $0.00 $129.3K $182.5K
Other Receivables $146.2K $0.00 $0.00
Total Short-Term Assets $63.87M $53.09M $30.07M
YoY Change 3434.76% 1207.4% 311.51%
LONG-TERM ASSETS
Property, Plant & Equipment $583.0K $720.7K $798.9K
YoY Change -20.04% -10.5% 0.57%
Goodwill $0.00
YoY Change
Intangibles $362.7K $408.6K $453.4K
YoY Change -33.26% -20.47% 3520.88%
Long-Term Investments
YoY Change
Other Assets $1.000M $1.000M
YoY Change
Total Long-Term Assets $2.278M $3.510M $2.693M
YoY Change -4.12% 37.65% 23.97%
TOTAL ASSETS
Total Short-Term Assets $63.87M $53.09M $30.07M
Total Long-Term Assets $2.278M $3.510M $2.693M
Total Assets $66.14M $56.60M $32.76M
YoY Change 1481.26% 756.21% 245.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.300M $1.204M
YoY Change -17.57% -32.99%
Accrued Expenses
YoY Change
Deferred Revenue $0.00
YoY Change
Short-Term Debt $527.4K $527.4K $527.4K
YoY Change
Long-Term Debt Due $527.4K $242.5K $232.5K
YoY Change
Total Short-Term Liabilities $2.029M $2.070M $1.964M
YoY Change -2.81% 31.23% 9.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.154M $1.219M
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $1.088M $1.154M $1.219M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.029M $2.070M $1.964M
Total Long-Term Liabilities $1.088M $1.154M $1.219M
Total Liabilities $3.117M $3.225M $3.183M
YoY Change 49.3% 104.41% 77.13%
SHAREHOLDERS EQUITY
Retained Earnings -$68.97M -$64.80M -$59.82M
YoY Change 32.49% 31.7% 29.04%
Common Stock $119.6M $106.2M $75.97M
YoY Change 183.41% 151.26% 80.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $51.07M $87.96M $29.58M
YoY Change
Total Liabilities & Shareholders Equity $66.14M $56.60M $32.76M
YoY Change 1481.26% 756.21% 245.61%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$4.173M -$4.980M -$5.308M
YoY Change 46.07% 75.0% 120.76%
Depreciation, Depletion And Amortization $119.7K $78.20K $77.86K
YoY Change -41.25% 11.56% 12.96%
Cash From Operating Activities -$2.683M -$5.663M -$5.721M
YoY Change 43.78% 44.82% -32.19%
INVESTING ACTIVITIES
Capital Expenditures -$16.18K $613.00
YoY Change -45.94% -99.24%
Acquisitions
YoY Change
Other Investing Activities $15.00K $0.00 $0.00
YoY Change
Cash From Investing Activities -$1.180K -$613.00
YoY Change -96.06% -99.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $30.00M $24.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.64M 28.59M 33.33M
YoY Change -15709.04% -2022223.97% 178.49%
NET CHANGE
Cash From Operating Activities -2.683M -5.663M -5.721M
Cash From Investing Activities -1.180K -613.0
Cash From Financing Activities 12.64M 28.59M 33.33M
Net Change In Cash 9.959M 22.93M 27.61M
YoY Change -603.73% -610.23% 683.06%
FREE CASH FLOW
Cash From Operating Activities -$2.683M -$5.663M -$5.721M
Capital Expenditures -$16.18K $613.00
Free Cash Flow -$2.667M -$5.663M -$5.721M
YoY Change 45.24% 41.9% -32.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Security12b Title
Security12bTitle
Common Shares, without par value
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1827761
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2087525
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
1827761
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
2087525
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
129269
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
67618
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
270405
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001684144
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
564051438
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Registrant Name
EntityRegistrantName
Zomedica Corp.
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Trading Symbol
TradingSymbol
zom
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
546654
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
690246
CY2019 us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
901
us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
88883
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
18256678
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3625083
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2539092
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
478835
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
187969
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
478835
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
197988
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2539092
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1082
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
135425
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
45399
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
273
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
810
CY2020Q3 us-gaap Assets
Assets
56604345
CY2019Q4 us-gaap Assets
Assets
4182984
CY2020Q3 us-gaap Assets Current
AssetsCurrent
53094317
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1806789
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2.</div></div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Basis of preparation</div></td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">The accounting policies set out below have been applied consistently in the condensed unaudited interim consolidated financial statements. The condensed unaudited interim consolidated financial statements do <div style="display: inline; font-style: italic; font: inherit;">not</div> include all of the information required for annual consolidated financial statements and should be read in conjunction with the Company's audited consolidated financial statements for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>are <div style="display: inline; font-style: italic; font: inherit;">not</div> necessarily indicative of the results that <div style="display: inline; font-style: italic; font: inherit;"> may </div>be expected for the year ending <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020.</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">These condensed unaudited interim consolidated financial statements were prepared using the same basis of presentation, accounting policies and methods of computation as those of the audited consolidated financial statements for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019.</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-style: italic;">Basis of consolidation</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">These condensed unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, Zomedica Pharmaceuticals, Inc.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">All inter-company accounts and transactions have been eliminated on consolidation.</div></div>
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29103049
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6981580
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
510586
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1940265
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52032640
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2487651
CY2020Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
22929591
CY2019Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4493929
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
51522054
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
547386
CY2020Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2019Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
564051438
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
108308398
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
564051438
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
108308398
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
87958137
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
38566820
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2020Q3 us-gaap Deposit Assets
DepositAssets
1561503
CY2019Q4 us-gaap Deposit Assets
DepositAssets
1033231
CY2020Q3 us-gaap Depreciation
Depreciation
78200
CY2019Q3 us-gaap Depreciation
Depreciation
70096
us-gaap Depreciation
Depreciation
232475
us-gaap Depreciation
Depreciation
201075
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
277150
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
232475
CY2020Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
78200
CY2019Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
70096
us-gaap Depreciation Nonproduction
DepreciationNonproduction
232475
us-gaap Depreciation Nonproduction
DepreciationNonproduction
201075
CY2020Q3 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
1827761
CY2019Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
2087525
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8321
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9403
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
144828
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
180144
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
46009
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
108
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1089
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1089
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
180144
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
21379
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
552798
CY2020Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
553411
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
408583
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
543395
CY2019 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
531419
us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
613
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2743
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1313
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1462
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-30
CY2020Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
CY2019Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-69834
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1308
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-69834
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1308
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1335085
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1377252
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3607346
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5490928
CY2020Q3 us-gaap Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset
ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
75234
CY2019Q3 us-gaap Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset
ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
1308
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1807889
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
400133
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
36525
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
437236
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
424501
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
412137
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
97357
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4979975
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2845679
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12738582
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16927016
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2020Q3 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-53228
CY2019Q3 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-19558
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
61651
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
22333
CY2020Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
96292
CY2019Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1378710
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-787124
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-798994
CY2020Q3 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
906300
CY2019Q3 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-21366
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
827538
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
76709
CY2020Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
243461
CY2019Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
122315
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
175553
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-140695
CY2020Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
CY2019Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
408583
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
543395
CY2020Q3 us-gaap Interest Expense
InterestExpense
CY2019Q3 us-gaap Interest Expense
InterestExpense
us-gaap Interest Expense
InterestExpense
732
us-gaap Interest Expense
InterestExpense
18338
CY2020Q3 us-gaap Interest Income Operating
InterestIncomeOperating
21238
CY2019Q3 us-gaap Interest Income Operating
InterestIncomeOperating
us-gaap Interest Income Operating
InterestIncomeOperating
21566
us-gaap Interest Income Operating
InterestIncomeOperating
CY2020Q3 us-gaap Interest Paid Net
InterestPaidNet
CY2019Q3 us-gaap Interest Paid Net
InterestPaidNet
12164
us-gaap Interest Paid Net
InterestPaidNet
651
us-gaap Interest Paid Net
InterestPaidNet
18338
CY2020Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
CY2019Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
792104
CY2020Q3 us-gaap Liabilities
Liabilities
3224556
CY2019Q4 us-gaap Liabilities
Liabilities
2087525
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56604345
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4182984
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2070252
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-657000
CY2020Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5662629
CY2019Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3910078
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13556283
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13767933
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4979975
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2845679
us-gaap Net Income Loss
NetIncomeLoss
-12738582
us-gaap Net Income Loss
NetIncomeLoss
-16927016
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5000433
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2844366
us-gaap Operating Income Loss
OperatingIncomeLoss
-12636486
us-gaap Operating Income Loss
OperatingIncomeLoss
-16927077
CY2020Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
CY2019Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
59097
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1396795
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
242491
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1154304
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
us-gaap Operating Lease Payments
OperatingLeasePayments
259616
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1380744
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1103658
CY2020Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
42448
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2087525
CY2020Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28592833
CY2019Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1414
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64071437
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14972319
CY2020Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-613
CY2019Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-582437
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1006900
CY2019Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
127345
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
382035
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1963
CY2019Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
7463
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
CY2020Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
80409
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
64889
CY2020Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2268217
CY2019Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1414
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5107615
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
627681
CY2020Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
12
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
12
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
12
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
12
CY2019Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
501487
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
501487
CY2020Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
613
CY2019Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
80950
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
613
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
155513
CY2020Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2019Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
11961397
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
11961397
CY2020Q3 us-gaap Prepaid Advertising
PrepaidAdvertising
32190
CY2019Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
19829
CY2020Q3 us-gaap Prepaid Insurance
PrepaidInsurance
258306
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
110636
CY2020Q3 us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
14347
CY2019Q3 us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
14347
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29997500
CY2019Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56496283
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3000000
CY2020Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
CY2019Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
12000000
us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
5400
us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
0
CY2020Q3 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
CY2019Q3 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
CY2020Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2019Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
600000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2020Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
863550
CY2019Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12155409
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
600000
CY2020Q3 us-gaap Professional Fees
ProfessionalFees
839646
CY2019Q3 us-gaap Professional Fees
ProfessionalFees
306937
us-gaap Professional Fees
ProfessionalFees
1413118
us-gaap Professional Fees
ProfessionalFees
1296884
CY2019 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
290513
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
299268
CY2019 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
2210
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
164117
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
987493
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1275796
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1410947
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
729142
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
720701
us-gaap Reclassifications
Reclassifications
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">21.</div></div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Comparative figures</div></td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had <div style="display: inline; font-style: italic; font: inherit;">no</div> effect on the reported results of operations. Adjustments have been made to the consolidated schedule of expenses for the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2019 </div>to classify health insurance benefits as part of salaries, wages and bonuses, and audit fees to professional fees. This change in classification does <div style="display: inline; font-style: italic; font: inherit;">not</div> affect previously reported cash flows from operating activities in the consolidated statements of cash flows.</div></div>
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2702103
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
962463
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7205674
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9555345
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64796423
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52057841
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.72
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
187969
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
197988
us-gaap Share Based Compensation
ShareBasedCompensation
478835
us-gaap Share Based Compensation
ShareBasedCompensation
2539092
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.18
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.19
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.19
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.11
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.13
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.28
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.87
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.99
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0028
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0021
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0049
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0024
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.003
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
150000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
15000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
30000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
15000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
15000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
400000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3750
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
10000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
675000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
75375
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
37500
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
515000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7571000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7495000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5056000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2000000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
175000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
40000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
300000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7040265
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13024640
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9136348
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.95
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.12
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.19
CY2019Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.19
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.19
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.19
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.19
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.19
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.19
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.19
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.18
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.13
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.11
CY2020Q3 us-gaap Share Price
SharePrice
0.17
CY2020Q2 us-gaap Share Price
SharePrice
0.19
CY2020Q1 us-gaap Share Price
SharePrice
0.18
CY2020Q3 us-gaap Share Price
SharePrice
0.10
CY2020Q3 us-gaap Share Price
SharePrice
0.13
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3888291
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
9136349
CY2020Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
394735
CY2019Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
792104
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
56496283
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
600000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3657000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
5033499
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2095459
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
53379789
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-style: italic;">Use of estimates</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">Areas where significant judgment is involved in making estimates are the determination of fair value of stock-based compensation, the useful lives of property and equipment, allocation of proceeds from financings to shares and warrants, fair value of placement agent warrants, and forecasting future cash flows for assessing the going concern assumption.</div></div></div></div>
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
550541878
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108038398
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
291314002
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105711459
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
550541878
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
108038398
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
291314002
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105711459
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
550541878
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108038398
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
291314002
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105711459
CY2020Q3 zom Accounts Payable And Accrued Liabilities Due Greater Than1 Year
AccountsPayableAndAccruedLiabilitiesDueGreaterThan1Year
CY2019Q4 zom Accounts Payable And Accrued Liabilities Due Greater Than1 Year
AccountsPayableAndAccruedLiabilitiesDueGreaterThan1Year
CY2020Q3 zom Accounts Payable And Accrued Liabilities Due In3 To6 Months
AccountsPayableAndAccruedLiabilitiesDueIn3To6Months
CY2019Q4 zom Accounts Payable And Accrued Liabilities Due In3 To6 Months
AccountsPayableAndAccruedLiabilitiesDueIn3To6Months
CY2020Q3 zom Accounts Payable And Accrued Liabilities Due In6 To9 Months
AccountsPayableAndAccruedLiabilitiesDueIn6To9Months
CY2019Q4 zom Accounts Payable And Accrued Liabilities Due In6 To9 Months
AccountsPayableAndAccruedLiabilitiesDueIn6To9Months
CY2020Q3 zom Accounts Payable And Accrued Liabilities Due In9 To12 Months
AccountsPayableAndAccruedLiabilitiesDueIn9To12Months
CY2019Q4 zom Accounts Payable And Accrued Liabilities Due In9 To12 Months
AccountsPayableAndAccruedLiabilitiesDueIn9To12Months
CY2020Q3 zom Accounts Payable And Accrued Liabilities Due Less Than3 Months
AccountsPayableAndAccruedLiabilitiesDueLessThan3Months
1827761
CY2019Q4 zom Accounts Payable And Accrued Liabilities Due Less Than3 Months
AccountsPayableAndAccruedLiabilitiesDueLessThan3Months
2087525
zom Adjustments To Equity Warrant Issued
AdjustmentsToEquityWarrantIssued
zom Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
280005613
CY2020Q3 zom Due To Related Parties3 To6 Months
DueToRelatedParties3To6Months
CY2019Q4 zom Due To Related Parties3 To6 Months
DueToRelatedParties3To6Months
CY2020Q3 zom Due To Related Parties6 To9 Months
DueToRelatedParties6To9Months
CY2019Q4 zom Due To Related Parties6 To9 Months
DueToRelatedParties6To9Months
CY2020Q3 zom Due To Related Parties9 To12 Months
DueToRelatedParties9To12Months
CY2019Q4 zom Due To Related Parties9 To12 Months
DueToRelatedParties9To12Months
CY2020Q3 zom Due To Related Parties Greater Than1 Year
DueToRelatedPartiesGreaterThan1Year
CY2019Q4 zom Due To Related Parties Greater Than1 Year
DueToRelatedPartiesGreaterThan1Year
CY2020Q3 zom Due To Related Parties Less Than3 Months
DueToRelatedPartiesLessThan3Months
1827761
CY2019Q4 zom Due To Related Parties Less Than3 Months
DueToRelatedPartiesLessThan3Months
2087525
CY2020Q3 zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
CY2019Q3 zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
19737
CY2020Q1 zom Issuance Of Common Shares And Warrants Direct Costs Of Issuance
IssuanceOfCommonSharesAndWarrantsDirectCostsOfIssuance
348220
CY2020Q2 zom Issuance Of Common Shares And Warrants Direct Costs Of Issuance
IssuanceOfCommonSharesAndWarrantsDirectCostsOfIssuance
582977
CY2020Q2 zom Issuance Of Common Shares And Warrants Direct Costs Of Issuance
IssuanceOfCommonSharesAndWarrantsDirectCostsOfIssuance
1908202
CY2020Q3 zom Issuance Of Common Shares And Warrants Direct Costs Of Issuance
IssuanceOfCommonSharesAndWarrantsDirectCostsOfIssuance
2268215
zom Issuance Of Common Shares And Warrants Direct Costs Of Issuance
IssuanceOfCommonSharesAndWarrantsDirectCostsOfIssuance
5107615
CY2020Q3 zom Noncash Rent Expense
NoncashRentExpense
6019
CY2019Q3 zom Noncash Rent Expense
NoncashRentExpense
zom Noncash Rent Expense
NoncashRentExpense
16051
zom Noncash Rent Expense
NoncashRentExpense
CY2019Q4 zom Number Of Lease Agreements
NumberOfLeaseAgreements
2
zom Operating Lease Liability Additions
OperatingLeaseLiabilityAdditions
1553611
zom Operating Lease Liability Interest
OperatingLeaseLiabilityInterest
102800
CY2020Q3 zom Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
172867
CY2020Q3 zom Operating Lease Right Of Use Asset Aggregate Lease Commitments
OperatingLeaseRightOfUseAssetAggregateLeaseCommitments
2067505
zom Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
275667
CY2020Q3 zom Operating Lease Right Of Use Asset Cost
OperatingLeaseRightOfUseAssetCost
1553611
CY2020Q3 zom Operating Lease Right Of Use Asset Impact Of Present Value
OperatingLeaseRightOfUseAssetImpactOfPresentValue
513894
zom Operating Lease Rightofuse Asset Interest
OperatingLeaseRightofuseAssetInterest
-102800
CY2020Q3 zom Prepaid Expenses And Deposits
PrepaidExpensesAndDeposits
1932408
CY2019Q4 zom Prepaid Expenses And Deposits
PrepaidExpensesAndDeposits
1228585
CY2020Q3 zom Prepaid Expenses And Deposits Current
PrepaidExpensesAndDepositsCurrent
932408
CY2019Q4 zom Prepaid Expenses And Deposits Current
PrepaidExpensesAndDepositsCurrent
1228585
CY2020Q3 zom Prepaid Expenses And Deposits Noncurrent
PrepaidExpensesAndDepositsNoncurrent
1000000
CY2019Q4 zom Prepaid Expenses And Deposits Noncurrent
PrepaidExpensesAndDepositsNoncurrent
0
CY2020Q3 zom Proceeds For Government Loan
ProceedsForGovernmentLoan
CY2019Q3 zom Proceeds For Government Loan
ProceedsForGovernmentLoan
zom Proceeds For Government Loan
ProceedsForGovernmentLoan
527360
zom Proceeds For Government Loan
ProceedsForGovernmentLoan
CY2020Q3 zom Proceeds From Refund Of Prepaid Rent
ProceedsFromRefundOfPrepaidRent
CY2019Q3 zom Proceeds From Refund Of Prepaid Rent
ProceedsFromRefundOfPrepaidRent
zom Proceeds From Refund Of Prepaid Rent
ProceedsFromRefundOfPrepaidRent
1002113
zom Proceeds From Refund Of Prepaid Rent
ProceedsFromRefundOfPrepaidRent
CY2020Q3 zom Property Plant And Equipment Including Leased Assets
PropertyPlantAndEquipmentIncludingLeasedAssets
2101445
CY2019Q4 zom Property Plant And Equipment Including Leased Assets
PropertyPlantAndEquipmentIncludingLeasedAssets
1832800
CY2020Q2 zom Stock Issued During Period Shares Exercise Of Warrants And Prefunded Warrants
StockIssuedDuringPeriodSharesExerciseOfWarrantsAndPrefundedWarrants
12162492
CY2020Q3 zom Stock Issued During Period Shares Exercise Of Warrants And Prefunded Warrants
StockIssuedDuringPeriodSharesExerciseOfWarrantsAndPrefundedWarrants
24984492
zom Stock Issued During Period Value Exercise Of Warrants And Prefunded Warrants
StockIssuedDuringPeriodValueExerciseOfWarrantsAndPrefundedWarrants
12155409
zom Stock Issued During Period Value Issued For Financing Net Of Cost
StockIssuedDuringPeriodValueIssuedForFinancingNetOfCost
14372319

Files In Submission

Name View Source Status
0001171843-20-007889-index-headers.html Edgar Link pending
0001171843-20-007889-index.html Edgar Link pending
0001171843-20-007889.txt Edgar Link pending
0001171843-20-007889-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_111220p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zom-20200930.xml Edgar Link completed
zom-20200930.xsd Edgar Link pending
zom-20200930_cal.xml Edgar Link unprocessable
zom-20200930_def.xml Edgar Link unprocessable
zom-20200930_lab.xml Edgar Link unprocessable
zom-20200930_pre.xml Edgar Link unprocessable